- Home
- PENN vs ACAD Comparison
PENN vs ACAD Comparison
Compare PENN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PENN
- ACAD
- Stock Information
- Founded
- PENN 1972
- ACAD 1993
- Country
- PENN United States
- ACAD United States
- Employees
- PENN N/A
- ACAD N/A
- Industry
- PENN Hotels/Resorts
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- PENN Consumer Discretionary
- ACAD Health Care
- Exchange
- PENN Nasdaq
- ACAD Nasdaq
- Market Cap
- PENN 2.3B
- ACAD 2.5B
- IPO Year
- PENN 1994
- ACAD 2004
- Fundamental
- Price
- PENN $17.05
- ACAD $22.71
- Analyst Decision
- PENN Buy
- ACAD Buy
- Analyst Count
- PENN 19
- ACAD 16
- Target Price
- PENN $23.03
- ACAD $27.00
- AVG Volume (30 Days)
- PENN 4.3M
- ACAD 1.6M
- Earning Date
- PENN 08-07-2025
- ACAD 08-05-2025
- Dividend Yield
- PENN N/A
- ACAD N/A
- EPS Growth
- PENN N/A
- ACAD N/A
- EPS
- PENN N/A
- ACAD 1.37
- Revenue
- PENN $6,643,700,000.00
- ACAD $996,283,000.00
- Revenue This Year
- PENN $7.93
- ACAD $13.39
- Revenue Next Year
- PENN $5.59
- ACAD $10.59
- P/E Ratio
- PENN N/A
- ACAD $16.65
- Revenue Growth
- PENN 5.51
- ACAD 22.42
- 52 Week Low
- PENN $13.25
- ACAD $13.40
- 52 Week High
- PENN $23.08
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- PENN 60.16
- ACAD 66.04
- Support Level
- PENN $15.58
- ACAD $21.35
- Resistance Level
- PENN $16.77
- ACAD $22.69
- Average True Range (ATR)
- PENN 0.62
- ACAD 0.76
- MACD
- PENN 0.15
- ACAD -0.13
- Stochastic Oscillator
- PENN 82.68
- ACAD 70.76
About PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media assets, theScore and ESPN (starting with its partnership launch in November 2023), provide access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.